Program
lead PB-212
Also written as “[212Pb]Pb-PSV359”, “[212Pb]Pb-MP0712” and “[212Pb]VMT-α-NET”.
Its studies are mostly in Stomach Neoplasms · Small Cell Lung Carcinoma · Gastro-enteropancreatic neuroendocrine tumor, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Perspective Therapeutics | 22 open or running | phase 2since Nov 15, 2022 | Nov 15, 2022 | Jan 31, 2028phase 2 · NCT06710756 |
| Molecular Partners | 11 open or running | phase 2since Nov 10, 2025 | Nov 10, 2025 | Sep 2028phase 2 · NCT07278479 |
Also a collaborator on its studies: orano-med-llc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 15, 2022First study: phase 2 study in Gastro-enteropancreatic neuroendocrine tumorNew to Perspective TherapeuticsPerspective Therapeutics · NCT05636618 · 300 planned · United States
- Nov 25, 2024Phase 2 study in Stomach NeoplasmsPerspective Therapeutics · NCT06710756 · 112 planned · United States
- Nov 10, 2025Molecular Partners's first study: phase 2 study in Small Cell Lung CarcinomaNew to Molecular PartnersMolecular Partners · NCT07278479 · 138 planned · United States
Ahead
- Jan 31, 2028Primary completion: phase 2 study in Stomach NeoplasmsPerspective Therapeutics · NCT06710756
- Sep 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaMolecular Partners · NCT07278479
- Nov 26, 2029Primary completion: phase 2 study in Gastro-enteropancreatic neuroendocrine tumorPerspective Therapeutics · NCT05636618
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07278479Small Cell Lung Carcinoma · United States | 2 | Recruiting | Molecular Partners | Sep 2028 | 138 |
| NCT06710756Stomach Neoplasms · United States | 2 | Recruiting | Perspective Therapeutics | Jan 31, 2028 | 112 |
| NCT05636618Gastro-enteropancreatic neuroendocrine tumor · United States | 2 | Recruiting | Perspective Therapeutics | Nov 26, 2029 | 300 |
How it is read
Names in the registry
- “[212Pb]Pb-PSV359”, 1 entry
- “[212Pb]Pb-MP0712”, 1 entry
- “[212Pb]VMT-α-NET”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
- Gastro-enteropancreatic neuroendocrine tumor, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.